Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Geron ( (GERN) ) just unveiled an update.
On March 10, 2025, John A. Scarlett, M.D. concluded his role as President, CEO, and Chairman of the Board at Geron Corporation, with Dawn C. Bir appointed as Interim President and CEO. This leadership transition is significant as it may impact Geron’s strategic direction and stakeholder interests, with Ms. Bir bringing extensive experience from her roles in various pharmaceutical companies.
More about Geron
Geron Corporation operates in the biopharmaceutical industry, focusing on the development of innovative therapeutics for the treatment of rare diseases.
YTD Price Performance: -55.28%
Average Trading Volume: 15,240,735
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.03B
Learn more about GERN stock on TipRanks’ Stock Analysis page.